Cd133 2 293c3 pe antibody

Manufactured by Miltenyi Biotec

Sourced in Germany

The CD133/2 (293C3)-PE antibody is a cell surface marker directed against the CD133 antigen. CD133 is a transmembrane glycoprotein that is expressed on various types of stem and progenitor cells. The CD133/2 (293C3)-PE antibody is conjugated to the fluorescent dye phycoerythrin (PE), allowing for the detection and analysis of CD133-positive cells using flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Facscalibur machine, by BD (2 mentions) Facscanto 2 cytometer, by BD (1 mentions) Cd133 1 microbeads, by Miltenyi Biotec (1 mentions) Fcr blocking reagent, by Miltenyi Biotec (1 mentions) Pre sort buffer, by BD (1 mentions) Facscanto 2, by BD (1 mentions) Annexin 5 fitc pi apoptosis detection kit, by BD (1 mentions)

Spelling variants of this product

CD133 (122 citations) CD133-PE (52 citations) CD133 antibody (15 citations) CD133-PE antibody (14 citations) CD133/2-PE (8 citations) CD133/2-PE antibody (5 citations) CD133/2 (293C3) (4 citations) CD133/2 (293C3)-PE (3 citations) CD133 (293C3) (2 citations)

5 protocols using cd133 2 293c3 pe antibody

Evaluating Btbd7 siRNA-Mediated Apoptosis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Aliquots of CD133⁺ cells were evaluated for purity by flow cytometry with a FACSCalibur machine (BD Biosciences, San Jose, CA, USA) using CD133/2 (293C3)-PE antibody (Miltenyi Biotec, Germany).
Cells were transfected with Btbd7 siRNA and treated with paclitaxel at 1 μM for 48 h, and then cells were collected for apoptosis detection and stained with annexin V–FITC and propidium iodide using the TACS Annexin V kit (Kaigen, Nanjing, P.R. China) according to the manufacturer’s protocol. All samples were analyzed using a BD FACSCanto II cytometer (BD Biosciences) with BD FACSDiva software. All experiments were performed in triplicate.

Fang L.Z., Zhang J.Q., Liu L., Fu W.P., Shu J.K., Feng J.G, & Liang X. (2017). Silencing of Btbd7 Inhibited Epithelial–Mesenchymal Transition and Chemoresistance in CD133+ Lung Carcinoma A549 Cells. Oncology Research, 25(5), 819-829.

+ Open protocol

+ Expand

Cell Surface Marker Staining

Check if the same lab product or an alternative is used in the 5 most similar protocols

Unfixed cells were stained with CD133/2(293C3)-PE antibody (Miltenyi Biotec) following manufacturer's protocol.

Tilghman J., Wu H., Sang Y., Shi X., Guerrero-Cazares H., Quinones-Hinojosa A., Eberhart C.G., Laterra J, & Ying M. (2014). HMMR Maintains the Stemness and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer research, 74(11), 3168-3179.

+ Open protocol

+ Expand

CD133+ Cell Isolation and Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

When the number of SC326 cells reached 2×10 7 in total, they were labeled with 1 μl CD133/1 microbeads (Miltenyi Biotec, Germany) per one million cells and sorted with CD133 magnetic sorting as previously described (Singh et al., 2004) . CD133 positive and negative cells were cultured for further experiments. Aliquots of CD133 positive and negative cells were evaluated for purity by flow cytometry with a FACSCalibur machine (BD Biosciences), using CD133/2 (293C3)-PE antibody (Miltenyi Biotec, Germany).

Qi L., Ren K., Fang F., Zhao D.H., Yang N.J, & Li Y. (2015). Over Expression of BCL2 and Low Expression of Caspase 8 Related to TRAIL Resistance in Brain Cancer Stem Cells. Asian Pacific journal of cancer prevention : APJCP, 16(12).

+ Open protocol

+ Expand

CD133+ Cell Enrichment under Hypoxia

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells in the logarithmic growth phase were cultured under hypoxic conditions or normal conditions for 24 h at 37°C. They were subsequently washed three times with PBS, collected by centrifugation at 300 × g for 5 min at room temperature, and resuspended and dissociated into single cell suspension in the Pre-Sort Buffer (BD FACS^™) by repeatedly pipetting. The cells were then centrifuged at 300 × g for 5 min at room temperature and the supernatant was discarded. The cells were washed with 8 ml PBS, blocked with 2 ml FcR Blocking Reagent (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) for 10 min at 4°C and incubated with 2 ml CD133/2 (293C3)-PE antibodies (dilution, 1:1,000; cat. no. 130-090-853; Miltenyi Biotec GmbH) for 10 min at 4°C in the dark. The cells were washed once with 2 ml PBS and then the proportion of CD133+ cells were detected using the BD FACSCalibur^™ analyzer with FlowJo 7.6 software.

Zeng F., Chen H., Zhang Z., Yao T., Wang G., Zeng Q., Duan S, & Zhan Y. (2018). Regulating glioma stem cells by hypoxia through the Notch1 and Oct3/4 signaling pathway. Oncology Letters, 16(5), 6315-6322.

+ Open protocol

+ Expand

Flow Cytometric Analysis of Cell Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

The CD133/2 (293C3)-PE antibodies (Miltenyi Biotec) were used to detect the CD133 membrane expression by flow cytometry (BD FACSCanto II, BD biosciences) according to the manufacturer's protocols. The FITC-Annexin V/PI apoptosis detection kit (BD) was used to detect the percentage of the apoptotic cell by flow cytometry (BD FACSCanto II) according to the manufacturer's protocols. In addition, propidium iodide (PI) staining was used to analyze the cell cycle by flow cytometry (BD FACSCanto II).

Wu J.E., Wu Y.Y., Tung C.H., Tsai Y.T., Chen H.Y., Chen Y.L, & Hong T.M. (2020). DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression. Theranostics, 10(19), 8903-8923.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!